Allopurinol Doesn't Increase All-Cause Mortality, Study Says
the MPR take:
Allopurinol initiators with hyperuricemia and gout have a modestly reduced risk of death, according to a study published in the Annals of the Rheumatic Diseases. The research analyzed a UK general population database for patients ≥40 years of age with a history of hyperuricemia (serum urate level >357μmol/L for women, >416μmol/L for men) from January 2000–May 2010. The group of 5,927 individuals receiving allopurinol had a lower risk of all-cause mortality compared to the matched control group (matched HR 0.89; 95% CI 0.80–0.99). These findings show that despite rare but potentially fatal adverse effects associated with allopurinol, the benefits of the most common treatment for lowering urate could outweigh this risk.
Background: Allopurinol is the most commonly used urate-lowering therapy, with rare but potentially fatal adverse effects. The study population included individuals aged 40 years who had a record of hyperuricaemia (serum urate level >357 mol/L for women and >416 mol/L for men) between January ...
READ FULL ARTICLE From ard.bmj.com